Shanghai MicroPort Medical announced that its Firehawk Rapamycin-eluting coronary stent was approved by China FDA. The product is the only targeted drug-eluting stent system in the world, the company said. Targeted unidirectional eluting technology with fully biodegradable polymers generates precisely controlled drug-release kinetics. The applied targeted eluting technology allows Firehawk to achieve the same clinical efficacy as other traditional DES with only one-third the dosage, the company said (Click Here For More - Chinese Language)

"China Successfully Developed The World’s First Rapamycin Target Eluting Coronary Stent" - health.people.com.cn (03/21/2014)

Shanghai MicroPort Gets China Approval For Targeted Drug-eluting Stent

More from China

More from Focus On Asia